|
|
Article: Dupuytren's Clinical Trial Results Announced at 48th Annual Orthopedic Research Society Meeting in Dallas.
- Article from:
- PR Newswire
- Article date:
- March 1, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
LYNBROOK, N.Y. -- BioSpecifics Technologies Corp. announced today that results of a Phase 2 placebo controlled double blind dose response trial using its product candidate Cordase(TM) were presented at the 48th Annual Meeting of the Orthopaedic Research Society (http://www.ors.org) in Dallas, TX. Dr. Marie Badalamente of the Department of Orthopaedics at Stony Brook University Hospital and Medical Center, Stony Brook, NY (http://www.uhmc.sunysb.edu/som/ortho.html) presented the results of the clinical trial on February 11. A total of eighty patients (64 male and 16 females) were treated in two centers; Stony Brook University Medical Center (Drs. Marie Badalamente and ...